December 2018 Vol 11, No 9
The American Hospital Association (AHA), which is arguably America’s most important voice for hospitals, periodically holds an executive forum in major cities across the country. This gives the leadership of the association an opportunity to meet local leaders and to continue to hone the message as to the future of hospitals in a quickly evolving delivery system.
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Pharmacist-Led Drug Therapy Problem Management in an Interprofessional Geriatric Care Continuum: A Subset of the PIVOTS Group
Ashley M. Campbell, PharmD, Kim C. Coley, PharmD, Jason M. Corbo, PharmD, Teresa M. DeLellis, PharmD, Matthew Joseph, PharmD, Carolyn T. Thorpe, PhD, MPH, Melissa S. McGivney, PharmD, Patricia Klatt, PharmD, Lora Cox-Vance, MD, Vincent Balestrino, MD, Heather Sakely, PharmD
Drug therapy problems, which are undesirable events that involve medications that can ultimately interfere with a patient’s therapeutic goals, are a major cause of morbidity, mortality, and hospitalizations in older adults.
Improving the Outcomes of Medication Use by Seniors
A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation in a Tertiary Eye Care Center
Eileen L. Mayro, BA, Laura T. Pizzi, PharmD, MPH, Lisa A. Hark, PhD, RD, Ann P. Murchison, MD, MPH, Douglas Wisner, MD, Anish Koka, MD, Benjamin E. Leiby, PhD, Nooreen Dabbish, PhD, Adedoyin Okulate, BS, Alexa Dessy, BA, Caitlin Green, BS, Robert Bailey, MD
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
The randomized, controlled Omadacycline in Acute Skin Structure Infections Study (OASIS)-2 study comparing omadacycline and linezolid for the treatment of adults with an acute bacterial skin and skin structure infection (ABSSSI) that is known or suspected to result from a gram-positive pathogen enrolled 735 patients, with 368 and 367 patients in each group, respectively.
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Results 1 - 8 of 8